Coverage
-
June 07, 2018
Biogen Inc. has settled a licensing dispute in a New Jersey federal court with a pharmaceutical company over whether the global biotech giant could keep collecting royalties on sales of the blood thinner Angiomax after the patent had expired.
1 other articles on this case.
View all »